

GP (2)

Attorney Docket No. 205,5
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Bischofberger et al.

Serial No.: 08/653,034

Group No.: 1205

Filed:

May 24, 1996

Examiner: ur

unassigned

For:

NOVEL COMPOUNDS AND METHODS FOR SYNTHESIS AND THERAPY

Assistant Commissioner for Patents

Washington, D.C. 20231

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT BEFORE MAILING DATE OF EITHER A FINAL ACTION OR NOTICE OF ALLOWANCE (37 CFR 1.97 (c))

TIME TRANSMITTAL OF ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

- 1. The information disclosure statement transmitted herewith is being filed *after* three months of the filing date of this national application or the date of entry of the national stage as set forth in § 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but *before* the mailing date of either:
 - (1) a final action under § 1.113 or
 - (2) a notice of allowance under § 1.311,

whichever occurs first.

CERTIFICATE OF MAILING (37 CFR 1.8 (a))

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: Fibrualy 12 1998 (Signature of person mailing paper)

(Type or print name of person mailing paper)

(Signature of person mailing paper)

CERTIFICATION OR FEE

| 2. Accompany this transmittal is | |
|--|---|
| | |
| A. a certification as specified in 37 CFR 1.97 (e) | |
| OR | |
| B. x the fee set forth in 37 CFR 1.17 (p) for submission of an information disclosure statement under § 1.97 (c). (\$240.00). | |
| FEE PAYMENT | |
| | |
| 3. Applicant elects the option to pay the fee set forth in 37 CFR 1.17 (p) for submission of an information disclosure statement under § 1.97 (c). (\$240.00). | |
| | Fee due \$ 240.00 |
| METHOD OF PAYMENT OF FEE | |
| 4. | |
| attached is check in the sum of \$ | |
| x charge Account No07-1250 | the sum of \$ 240.00 |
| A duplicate of this request is attached. | |
| If any additional fees are due, please charge Account No. 07-1250 | |
| Reg. No. 35,071 | Mak n |
| | SIGNATURE OF ATTORNEY |
| | Mark L. Bosse |
| 7 | Type or print name of attorney |
| | Gilead Sciences, Inc. 333 Lakeside Drive |
| | P.O. Address |
| <u>.</u> | Foster City, CA 94404 |



GAU 1205 1614 \$

Attorney Docket No. 205.5
PATENT

IN THE ONITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Bischofberger et al.

Serial No.:

08/653.034

Group No.: 1205

Filed:

May 24, 1996

Examiner:

unassigned

For:

NOVEL COMPOUNDS AND METHODS FOR SYNTHESIS AND THERAPY

Assistant Commissioner for Patents

Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT (modified)

List of Sections Forming Part of This Information Disclosure Statement.

The following sections are being submitted for this Information Disclosure Statement:


1. x Preliminary Statements

2. X FORM PTO - 1449 (Modified)

3. X Copies of Listed Information Items Accompanying This Statement

RECEIVED

FEB 2 3 1993



Section 1. Preliminary statements

Applicants submit herewith patents, publications or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 CFR 1.97 (g)), an admission that the information cited is, or is considered to be, material to patentability or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Robin Torres

(Type or print name of person mailing paper)

Date

(Signature of person mailing paper)

02/20/1998 GPAYNE

00000046 DA#:071250 240.00 CH 08653034



Section 3. Copies of Listed Information Items Accompanying This Statement

Legible copies of all items listed in Form PTO-1449 accompany this information statement.

Reg. No. 35,071

SIGNATURE OF ATTORNEY

Tel. No.: (650) 572-6569

Mark L. Bosse

Type or print name of attorney

Gilead Sciences, Inc. 333 Lakeside Drive

P.O. Address

Foster City, CA 94404